Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (NCT04787042)
A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies
🩺 Plain-English Summary (8th-Grade Level)
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monotherapy arm is also planned; the exact design of the Phase 2 study elements with respect to formulation and pre-treatment will be determined after completion of the Phase 1 study portion of the trial.
Who can join: Review the eligibility criteria below.
Location: HonorHealth Research Institute — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- HonorHealth Research Institute — Scottsdale, Arizona
- Sarah Cannon Research Institute at HealthONE — Denver, Colorado
- Yale Cancer Center — New Haven, Connecticut
- Moffitt Cancer Center — Tampa, Florida
- Massachusetts General Hospital — Boston, Massachusetts
- Roswell Park Cancer Institute — Buffalo, New York
📞 Contact the Study Coordinator
Phone: (805) 300-3912
Email: beatrice@simchatherapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cancer
- Ovarian Tissue Cryopreservation in Children — Rochester, Minnesota
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study — Aurora, Colorado
- Ex Onc SLED: A Study Utilizing A Weighted Sled for Horizontal Resistance Training — Pittsburgh, Pennsylvania
- An Internet-based Program to Help Cancer Survivors Manage Pain — Fort Smith, Arkansas
- Identification of Patients With Age-Related Clonal Hematopoiesis (ARCH) Among Cancer Survivors — Toronto, Ontario
- Researching the Effect of Aerobic Exercise on Cancer — Los Angeles, California
Explore by condition: All Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.